Danco Laboratories filed an emergency application with the Supreme Court on Saturday, one day after a three-judge panel of the Fifth Circuit Court of Appeals temporarily blocked a Biden-era policy that allowed mifepristone, the chemical abortion pill, to be distributed by mail. The move sets up what could become the most consequential abortion case to reach the high court since the Dobbs decision, and it landed with the speed of a company that knows the legal ground is shifting beneath it.
The New York City-based drugmaker, which markets mifepristone under the brand name Mifeprex, asked the justices to stay the appeals court ruling while the broader case proceeds. Danco is not the only manufacturer seeking relief. Fox News reported that GenBioPro also filed an emergency request, and that both applications were directed to Justice Samuel Alito.
At stake is whether the FDA can unilaterally dismantle the in-person dispensing safeguards that governed mifepristone for more than two decades, and whether states like Louisiana, which have outlawed abortion and classified the drug as a controlled substance, have any say in how it crosses their borders.
The FDA first approved mifepristone in 2000. For over twenty years, women were required to obtain the drug in person from a certified provider. That changed in 2021, when the agency cited the COVID-19 pandemic as justification for allowing mail-order distribution. Two years later, the FDA made the policy permanent, no longer tethered to any public-health emergency.
That sequence matters. What began as a pandemic workaround became a permanent expansion of abortion access, executed entirely through regulatory action rather than legislation. Louisiana pushed back. In 2024, it became the first state in the country to classify mifepristone as a controlled and dangerous substance. Abortion is illegal in the state, with limited maternal health exceptions.
The Supreme Court has become the central arena for legal fights originating in Louisiana, and this case is no exception. The state's lawsuit against the FDA argues that the mail-order policy creates a pipeline for the drug to reach women inside its borders, overriding state law.
The Fifth Circuit panel agreed. In its Friday ruling, the judges wrote that the federal regulation "creates an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law." The New Orleans-based court has appellate jurisdiction over cases from Louisiana, Mississippi, and Texas.
Louisiana's lawsuit includes the story of Rosalie Markezitch, a Louisiana woman who said her boyfriend coerced her into having an abortion using mifepristone pills he ordered by mail from California. The complaint argues that under the old in-person requirement, Markezitch would have had the protection of a private medical appointment, and the chance to tell a doctor she did not want the abortion.
The lawsuit states: "Rosalie would have received the protection of a private in-person medical appointment. And if she had been able to tell a doctor that she did not want an abortion, the drugs that took her baby's life would never have been provided."
That is the human cost the mail-order regime's defenders prefer not to discuss. When abortion pills arrive in a mailbox, the safeguards that once stood between a vulnerable woman and a coercive partner vanish. The in-person requirement was not just a bureaucratic hurdle. It was a checkpoint, one that gave women a private moment with a medical professional, free from outside pressure.
The broader political landscape around the Supreme Court has been a source of anxiety for Democrats, who have watched the justices take up case after case that tests the limits of progressive regulatory overreach.
Danco's attorneys framed the Fifth Circuit's order as a radical departure from legal norms. In their application, they wrote:
"It bears emphasis how unprecedented the Fifth Circuit's order is. Never before has a federal court purported to immediately enjoin a several years' old drug approval; restrict a distribution system for that drug that manufacturers, providers, patients, and pharmacies have all been using for years; or reinstate conditions that FDA [Food and Drug Administration] determined do not meet the mandatory statutory criteria."
The drugmaker also pointed to procedural history, arguing that earlier stages of the litigation had provided transition time before any injunction took effect. Danco's filing stated: "The Alliance district court provided for time to appeal before its injunction would take effect, and when the Fifth Circuit later ruled on the merits, the Court of Appeals specifically highlighted the time FDA and Danco would have to prepare before any injunction took effect as a result of this Court's stay."
The Washington Times reported that Danco argued the ruling caused "immediate chaos" and "irreparable harm," and that the company told the court: "It is now unclear whether pharmacies nationwide may still dispense mifepristone to women tonight."
GenBioPro CEO Evan Masingill struck a more combative tone. Just The News reported that the lower-court ruling bars doctors from prescribing mifepristone via telehealth or sending it by mail, and Masingill said: "The Supreme Court must reject this unfounded and baseless attack on an essential medication."
Danco claims more than six million patients in the United States have used the drug. That figure is meant to suggest the mail-order system is too entrenched to reverse. But scale does not equal safety, and widespread use does not equal lawful distribution, especially when a state has explicitly classified the substance as controlled and dangerous.
The company's "unprecedented" argument also cuts both ways. It was equally unprecedented for the FDA to strip away in-person dispensing requirements for a powerful drug based on a pandemic rationale, then make the change permanent after the emergency ended. If the regulatory expansion was extraordinary, a judicial correction is hardly surprising.
President Donald Trump appointed two of the three Fifth Circuit judges on the panel that issued Friday's ruling. Former President George W. Bush appointed the third, as Politico reported. That detail will inevitably become a talking point for those who want to frame the decision as partisan rather than engage with its legal reasoning.
Democrats have repeatedly found themselves reacting to Supreme Court developments that reshape the political and legal terrain. High-profile figures have attacked the Court when its rulings cut against progressive priorities, a pattern likely to intensify if the justices take up the mifepristone question on the merits.
At its core, this case is about whether a federal agency can use regulatory power to override a state's criminal law. Louisiana banned abortion. Louisiana classified mifepristone as a controlled substance. The FDA's mail-order policy created a direct channel for the drug to reach Louisiana residents anyway, shipped from out of state, prescribed by out-of-state providers, with no in-person medical visit and no opportunity for a doctor to screen for coercion.
The Fifth Circuit recognized this tension plainly. The appeals court did not invent a new legal theory. It simply observed that the federal regulation functioned as an end-run around state law.
Whether the Supreme Court agrees to stay the ruling, or lets it stand while the case proceeds, will signal how seriously the justices take the federalism concerns at the heart of the dispute. The Court has not yet acted publicly on Danco's application, and the timeline for a response remains unclear.
The political fallout from major Supreme Court decisions has reshaped electoral calculations in recent cycles, and the mifepristone fight carries the same potential to energize both sides heading into the midterms.
Fox News reported that the emergency applications were directed to Justice Alito, and that the Court could act quickly on whether to pause the Fifth Circuit's ruling while litigation continues. The speed of Danco's filing, just one day after the appeals court acted, suggests the company expects the justices to move fast.
The open questions are significant. Did the Fifth Circuit's ruling block only mail distribution, or did it also reimpose other conditions the FDA had loosened? Will the Supreme Court issue a narrow administrative stay, or signal something broader about the FDA's authority over drug-access policies that conflict with state law? And will the justices treat this as a straightforward regulatory dispute, or as the next chapter in the post-Dobbs reckoning over where abortion policy is actually decided?
For twenty years, the in-person requirement protected women like Rosalie Markezitch. The FDA dismantled it by executive fiat. A federal appeals court put it back. Now the Supreme Court will decide whether the bureaucracy or the democratic process gets the final word, and whether a pill in a mailbox outranks a state's right to protect its own citizens.
